CERBIOS APPOINTS FRANCESCA SCARPITTA AS NEW DIRECTOR STRENGTENING ITS HIGH POTENCY APIs MANUFACTURING TEAM
Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units.
Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m3) started. In 2000 we successful passed the first FDA inspection for an HPAI production with no 483.
This new position was created in order to further strengthen our team in the development and manufacturing of HPAIs, where we have reached a significant exponential growth over the past decade.
As part of our strategy, we have constantly made and will make new investments to expand capacity as well as to keep the highest standard of innovative technology and quality in the industry, with the aim to be a major and recognized player as CDMO for Drug Substances needing high containment where the safety of the operators if essential.
“Dr. Scarpitta brings in a strong expertise and knowledge in the transfer of API manufacturing from R&D. Scale-up improvements following the development of the HPAI from clinical to commercial scale is one of her key competences“ confirms Dr. Gabriel Haering, CEO
“Thanks to her contribution we will further boost Cerbios’ vision of excellence in the manufacturing segment of the HPAI contract manufacturing arena which is a fast growing activity with further new investments in the near future”.
About Francesca Scarpitta.
Holds a PhD in Organic Chemistry at the University of Pavia. Since 2000 she grew her career in the API industry in Italy and in Israel, having various position in the R&D and in the Operations.
Since over 10 years she has roles of responsibility in the manufacturing of HPAI.
For more details see her profile at this link.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.
Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.